Patterns and progress in ovarian cancer over 14 years

被引:133
作者
Chan, John K.
Cheung, Michael K.
Husain, Amreen
Teng, Nelson N.
West, Dee
Whittemore, Alice S.
Berek, Jonathan S.
Osann, Kathryn
机构
[1] Stanford Univ, Sch Med, Stanford Canc Ctr, Div Gynecol Oncol,Dept Obstet & Gynecol, Stanford, CA 94305 USA
[2] Stanford Univ, Div Epidemiol, Dept Hlth Res & Policy, Stanford, CA 94305 USA
[3] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Orange, CA 92668 USA
关键词
D O I
10.1097/01.AOG.0000231680.58221.a7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To estimate the change in survival rates of women with ovarian cancer during the past 14 years. METHODS: Women diagnosed with epithelial, germ cell, sarcomas, and sex-cord stromal ovarian tumors were identified from the Surveillance Epidemiology and End Results Database. Demographic and clinicopathologic factors, and survival information were extracted and tested using chi(2) and Kaplan-Meier and Cox regression analyses. RESULTS: A total of 30,246 women were diagnosed with ovarian cancer, including 26,753 non-clear cell epithelial, 1,411 clear cell, 818 sarcoma, 778 germ cell, and 486 sex-cord stromal tumors. The 5-year disease-specific survival rate across 1988-1992 and 1993-1997 improved from 45.4% to 48.6% (P<.001). The corresponding estimates show increases for non-clear cell epithelial carcinoma from 42.5% to 45.8% (P<.001), and for sarcomas from 33.5% to 38.8% (P=.07). However, improvements were not observed in those with clear cell, 64.3% to 63.9% (P=.82), and sex-cord stromal, 89.7% to 85.7% (P=.18), tumors of the ovary. In multivariable analyses, younger age, early stage, favorable histologic cell types, low-grade tumors, standard surgery, and recent time interval from 1993-1997 were independent prognostic factors for improved survival. CONCLUSION: In this large population-based study, there has been some improvement in the overall survival of women with ovarian cancers during a 14-year period. However, new treatment strategies are warranted for those with epithelial cancer and sarcomas of the ovary, given their overall poor prognosis. These results from our updated analyses might help to counsel women diagnosed with ovarian cancers.
引用
收藏
页码:521 / 528
页数:8
相关论文
共 26 条
  • [21] Comparative study of ovarian cancer histopathology by registry pathologists and referral pathologists: A study by the Gilda Radner Familial Ovarian Cancer Registry
    Piver, MS
    Tsukada, Y
    Werness, BA
    DiCioccio, RA
    Whittemore, AS
    Ponder, BAJ
    [J]. GYNECOLOGIC ONCOLOGY, 2000, 78 (02) : 166 - 170
  • [22] ANALYSIS OF PROGNOSTIC FACTORS IN STAGE-I EPITHELIAL OVARIAN-CARCINOMA - IMPORTANCE OF DEGREE OF DIFFERENTIATION AND DEOXYRIBONUCLEIC-ACID PLOIDY IN PREDICTING RELAPSE
    VERGOTE, IB
    KAERN, J
    ABELER, VM
    PETTERSEN, EO
    DEVOS, LN
    TROPE, CG
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 169 (01) : 40 - 52
  • [23] Virnig BA, 2002, MED CARE, V40, P49
  • [24] ADJUVANT THERAPY OF OVARIAN GERM-CELL TUMORS WITH CISPLATIN, ETOPOSIDE, AND BLEOMYCIN - A TRIAL OF THE GYNECOLOGIC-ONCOLOGY-GROUP
    WILLIAMS, S
    BLESSING, JA
    LIAO, SY
    BALL, H
    HANJANI, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) : 701 - 706
  • [25] YANCIK R, 1993, CANCER, V71, P517
  • [26] ADJUVANT THERAPY IN STAGE-I AND STAGE-II EPITHELIAL OVARIAN-CANCER - RESULTS OF 2 PROSPECTIVE RANDOMIZED TRIALS
    YOUNG, RC
    WALTON, LA
    ELLENBERG, SS
    HOMESLEY, HD
    WILBANKS, GD
    DECKER, DG
    MILLER, A
    PARK, R
    MAJOR, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (15) : 1021 - 1027